Does Dr. NANCY EFFERSON-BONACHEA have financial conflicts of interest?

Dr. NANCY EFFERSON-BONACHEA (M.D.) has received a total of $546 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $546 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. NANCY EFFERSON-BONACHEA?

According to CMS Open Payments data, Dr. NANCY EFFERSON-BONACHEA received funding from APELLIS PHARMACEUTICALS ($274), REGENERON HEALTHCARE SOLUTIONS ($144), and GENENTECH USA ($111).

Does Dr. NANCY EFFERSON-BONACHEA receive research grants or speaking fees?

Dr. NANCY EFFERSON-BONACHEA has received $546 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. NANCY EFFERSON-BONACHEA

M.D.Real-Time Hydrated

Specialty: Ophthalmology

Practice Location: MANCHESTER, NH 03102

NPI Number: 1932173234

LIFETIME INDUSTRY VALUE

$546

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. EFFERSON-BONACHEA is a verified Ophthalmology practitioner based in MANCHESTER, NH.

Between 2021 and 2025, Dr. EFFERSON-BONACHEA had an overall industry promotional and research financial footprint of $546 as recorded in the federal CMS Open Payments database.

$546 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. EFFERSON-BONACHEA's primary funding source is APELLIS PHARMACEUTICALS, which accounts for $274 (representing 50.2% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

APELLIS PHARMACEUTICALS

Rank 1

$274

50.2%

REGENERON HEALTHCARE SOLUTIONS

Rank 2

$144

26.4%

GENENTECH USA

Rank 3

$111

20.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.